Featured
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Priothera Appoints Dr. Jens Hasskarl as Chief Medical Officer to Drive Late-Stage Clinical Development of Mocravimod, a S1P Receptor Modulator for Acute Myeloid Leukemia (AML)
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Anthem Blue Cross/Blue Shield
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
Vivasure Medical Receives CE Mark Approval in Europe for PerQseal Elite Vascular Closure System
Neuromod Closes €10m Financing to Accelerate Commercialisation
Neuromod Closes €10m Financing to Accelerate Commercialisation
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
XyloCor Therapeutics Raises $67.5 Million in Series B Financing to Advance Clinical Development of Novel Gene Therapy in Cardiovascular Disease
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
Vivasure Announces Positive Results of PATCH IDE Pivotal Study Indicating Safety and Efficacy of PerQseal® Large Hole Closure Device
Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus Dysfunction
Mainstay Medical Announces New ICD-10 Diagnosis Code for Multifidus Dysfunction
NEUROMARK® Treatment for Chronic Rhinitis Yields Significant Clinical Improvements
NEUROMARK® Treatment for Chronic Rhinitis Yields Significant Clinical Improvements
Lenire Controlled Clinical Trial Results Published in Nature Communications
Lenire Controlled Clinical Trial Results Published in Nature Communications
MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System
MMI Completes World’s First Robotic Preclinical Study in Neurosurgery with Symani® Surgical System
Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System
Mainstay Medical Announces Receipt of European and Australian Approvals of MRI Labeling on ReActiv8® Restorative Neurostimulation System
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
MMI Builds Global Momentum with Multiple Distribution Agreements and Regulatory Approvals
Neuromod's FDA-Approved Lenire Device Now a Treatment Option for 2.9 Million US Veterans with Tinnitus
Neuromod's FDA-Approved Lenire Device Now a Treatment Option for 2.9 Million US Veterans with Tinnitus
Neurent Medical Announces Publication of Positive Long-Term Results from Study on Chronic Rhinitis Treatment
Neurent Medical Announces Publication of Positive Long-Term Results from Study on Chronic Rhinitis Treatment
XyloCor Therapeutics Positive EXACT Phase 2 Data for XC001 Simultaneously Presented at SCAI 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions
XyloCor Therapeutics Positive EXACT Phase 2 Data for XC001 Simultaneously Presented at SCAI 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions
Vivasure Medical Announces First Large Hole Venous Patient Treated with PerQseal Elite Vascular Closure System
Vivasure Medical Announces First Large Hole Venous Patient Treated with PerQseal Elite Vascular Closure System
MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.
MMI Receives FDA Authorization to Commercialize Symani® Surgical System in the U.S.
Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure
Corteria Pharmaceuticals announces initiation of Phase 1 study to evaluate CRF2 agonist COR-1167 for treatment of worsening heart failure
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up
Mainstay Medical Announces Publication of the First Neuromodulation Study for Low Back Pain with 5-Year Follow-Up
Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients
Mainstay Medical Announces Publication of Clinical Results Comparing Older Patients and Younger Patients
Mainstay Medical Announces US$125 Million Equity Financing Transaction
Mainstay Medical Announces US$125 Million Equity Financing Transaction
MMI Raises $110 Million in Series C Financing
MMI Raises $110 Million in Series C Financing
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM
Mainstay Medical Announces Receipt of FDA Approval for MRI Labeling on ReActiv8® Restorative Neurostimulation SystemTM
Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock
Inotrem Successfully Reaches Agreement with the FDA for a Phase 3 Registration Trial for Nangibotide in Septic Shock
Calypso Enters into Agreement to Be Acquired by Novartis
Calypso Enters into Agreement to Be Acquired by Novartis
Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors
Corteria Pharmaceuticals appoints Mark Pruzanski as Chairman of its Board of Directors
US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies
Vivasure Medical Announces 100th Patient Enrolled in U.S. Pivotal Study
Vivasure Medical Announces 100th Patient Enrolled in U.S. Pivotal Study
 
 

We want to hear from you

If you are an entrepreneur with an ambitious plan, use the button below to say hello.